SRC and head and neck squamous cell carcinoma: The result showed that the CI of the combination of saracatinib and erlotinib was higher than that of the combination of saracatinib and capivasertib at the same dose of each drugs (0.51 vs 0.38 in HN12 cells, and 0.58 vs 0.47 in HN17 cells), suggesting that additional capivasertib treatment is worthy of future clinical investigation in HNSCC patients who are lack of clinical efficacy of anti-Src single agent.